Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial
…, L Andersen, S Bohn, J Paul, O Zhang, C Doram… - The Lancet, 2020 - thelancet.com
Background Nerinetide, an eicosapeptide that interferes with post-synaptic density protein
95, is a neuroprotectant that is effective in preclinical stroke models of ischaemia-reperfusion. …
95, is a neuroprotectant that is effective in preclinical stroke models of ischaemia-reperfusion. …
Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised …
…, A Poppe, A Sehgal, Q Zhang, BC Lethebe, C Doram… - The Lancet, 2022 - thelancet.com
Background Intravenous thrombolysis with alteplase bolus followed by infusion is a global
standard of care for patients with acute ischaemic stroke. We aimed to determine whether …
standard of care for patients with acute ischaemic stroke. We aimed to determine whether …
Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of COVID-19: a randomized controlled trial
…, ME Boesen, G Cerchiaro, C Doram… - … Open Access Journal, 2021 - cmajopen.ca
Background: Identification of therapies to prevent severe COVID-19 remains a priority. We
sought to determine whether hydroxychloroquine treatment for outpatients with SARS-CoV-2 …
sought to determine whether hydroxychloroquine treatment for outpatients with SARS-CoV-2 …
Alteplase compared to tenecteplase in patients with acute ischemic stroke (AcT) trial: protocol for a pragmatic registry linked randomized clinical trial
…, G Hunter, A Sehgal, Q Zhang, C Doram… - Stroke: Vascular and …, 2022 - Am Heart Assoc
Background: Intravenous thrombolysis with alteplase is widely used in acute ischemic stroke
patients presenting early after symptom onset. Recent phase II trials have suggested that …
patients presenting early after symptom onset. Recent phase II trials have suggested that …
Act trial: protocol for a pragmatic Registry‐Linked randomized clinical trial
…, G Hunter, A Sehgal, Q Zhang, C Doram… - Stroke: Vascular and …, 2022 - Am Heart Assoc
Background Intravenous thrombolysis with alteplase is widely used in patients with acute
ischemic stroke presenting early after symptom onset. Recent phase II trials have suggested …
ischemic stroke presenting early after symptom onset. Recent phase II trials have suggested …
Quality of Life After Intravenous Thrombolysis for Acute Ischemic Stroke: Results From the AcT Randomized Controlled Trial
BACKGROUND: Recent evidence from thrombolysis trials indicates the noninferiority of
intravenous tenecteplase to intravenous alteplase with respect to good functional outcomes in …
intravenous tenecteplase to intravenous alteplase with respect to good functional outcomes in …
Abstract WMP11: Health-related Quality Of Life After Thrombolysis In Acute Stroke: Results From The Act Trial
…, CC Kenney, A Sehgal, Q Zhang, C Doram… - Stroke, 2023 - Am Heart Assoc
Background and aims: Recent evidence from thrombolysis trials indicate the non-inferiority of
the Tenecteplase (TNK) to the Alteplase (TPA) with respect to functional outcomes in acute …
the Tenecteplase (TNK) to the Alteplase (TPA) with respect to functional outcomes in acute …
[PDF][PDF] Technology Roadmapping for Stroke Patients Assessment: Hospitalization Phase and Home Monitoring
I Yankovyi - Technology, 2023 - prism.ucalgary.ca
Stroke is a worldwide problem, with over 13.7 million new strokes each year and the second
commonest cause of death in the world. If it is not fatal, a stroke can result in permanent …
commonest cause of death in the world. If it is not fatal, a stroke can result in permanent …
Improving the reliability of stroke disability grading in clinical trials and clinical practice: the Rankin Focused Assessment (RFA)
JL Saver, B Filip, S Hamilton, A Yanes, S Craig, M Cho… - Stroke, 2010 - Am Heart Assoc
Background and Purpose— The modified Rankin Scale rates global disability after stroke
and is the most comprehensive and widely used primary outcome measure in acute stroke …
and is the most comprehensive and widely used primary outcome measure in acute stroke …
[PDF][PDF] Confidential
I Schwartz, ME Boesen, G Cerchiaro, C Doram… - cmajopen.ca
… Schwartz I, Boesen ME, Cerchiaro G, Doram C, Edwards BD, Ganesh A, Greenfield J,
Jamieson S, Karnik V, Kenney C, Lim R, Menon BK, Mponponsuo K, Rathwell S, Ryckborst …
Jamieson S, Karnik V, Kenney C, Lim R, Menon BK, Mponponsuo K, Rathwell S, Ryckborst …